 Mereo BioPharma Group plc NASDAQ: MREO, AIM: MPH, Mereo or the Company, today announced that it has entered into a Securities Purchase Agreement the Agreement with a new U.S.-based institutional healthcare investor. Under the terms of the Agreement, the institutional investor has agreed to make an investment of 3 million to purchase 12,252,715 of the Companys ordinary shares equivalent to 2,450,543 American Depository shares ADSs at a price equivalent to 18.8 pence per share, which represents a 20 discount over Mereos closing share price of 23.5 pence on AIM on February 18, 2020. Mereo intends to use the net proceeds from the private offering for general corporate purposes, including clinical trial activity and working capital. 